Follow
Jakob Ribbing
Jakob Ribbing
Unknown affiliation
Verified email at pharmetheus.com
Title
Cited by
Cited by
Year
Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming
L Lindbom, J Ribbing, EN Jonsson
Computer methods and programs in biomedicine 75 (2), 85-94, 2004
7722004
Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming
L Lindbom, J Ribbing, EN Jonsson
Computer methods and programs in biomedicine 75 (2), 85-94, 2004
7722004
Power, selection bias and predictive performance of the population pharmacokinetic covariate model
J Ribbing, E Niclas Jonsson
Journal of pharmacokinetics and pharmacodynamics 31, 109-134, 2004
1852004
The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models
J Ribbing, J Nyberg, O Caster, EN Jonsson
Journal of pharmacokinetics and pharmacodynamics 34 (4), 485-517, 2007
1052007
A model for glucose, insulin, and beta‐cell dynamics in subjects with insulin resistance and patients with type 2 diabetes
J Ribbing, B Hamrén, MK Svensson, MO Karlsson
The Journal of Clinical Pharmacology 50 (8), 861-872, 2010
462010
A pharmacokinetic comparison of anrukinzumab, an anti‐IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients
F Hua, J Ribbing, W Reinisch, F Cataldi, S Martin
British journal of clinical pharmacology 80 (1), 101-109, 2015
422015
Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second
X Wang, D Shang, J Ribbing, Y Ren, C Deng, T Zhou, F Guo, W Lu
European journal of clinical pharmacology 68, 1157-1166, 2012
162012
Characterizing Systemic Exposure of Inhaled Drugs: Application to the Long-Acting β2-Agonist PF-00610355
PM Diderichsen, E Cox, SW Martin, A Cleton, J Ribbing
Clinical pharmacokinetics 52 (6), 443-452, 2013
152013
Translating pharmacometrics to a pharmacoeconomic model of COPD
JF Slejko, RJ Willke, J Ribbing, P Milligan
Value in Health 19 (8), 1026-1032, 2016
132016
A model‐based longitudinal meta‐analysis of FEV1 in randomized COPD trials
J Korell, SW Martin, MO Karlsson, J Ribbing
Clinical Pharmacology & Therapeutics 99 (3), 315-324, 2016
122016
Longitudinal FEV1 dose–response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease
JC Nielsen, MM Hutmacher, A Cleton, SW Martin, J Ribbing
Journal of pharmacokinetics and pharmacodynamics 39 (6), 619-634, 2012
122012
Predicted heart rate effect of inhaled PF‐00610355, a long acting β‐adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease
PM Diderichsen, E Cox, SW Martin, A Cleton, J Ribbing
British Journal of Clinical Pharmacology 76 (5), 752-762, 2013
112013
Covariate Model Building in Nonlinear Mixed Effects Models
J Ribbing
Acta Universitatis Upsaliensis, 2007
72007
Population repeated time‐to‐event analysis of exacerbations in asthma patients: a novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and …
RJ Svensson, J Ribbing, N Kotani, M Dolton, S Vadhavkar, D Cheung, ...
CPT: pharmacometrics & systems pharmacology 10 (10), 1221-1235, 2021
62021
A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA
R Fogel, K Shields, J Christensen, J Ribbing, G Langdon, ...
European Respiratory Journal 42 (Suppl 57), 2013
52013
Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
A Moein, T Lu, S Jönsson, J Ribbing, N Kassir, W Zhang, G Sperinde, ...
CPT: Pharmacometrics & Systems Pharmacology 11 (9), 1244-1255, 2022
42022
Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
N Kassir, R Zhu, A Moein, J Langenhorst, J Ribbing, R Zhang, MT Tang, ...
CPT: Pharmacometrics & Systems Pharmacology 11 (9), 1234-1243, 2022
42022
Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma
N Kotani, M Dolton, RJ Svensson, J Ribbing, LE Friberg, S Vadhavkar, ...
The Journal of Clinical Pharmacology 62 (7), 905-917, 2022
42022
Assessing the therapeutic benefit of a new inhaled QD LABA through population PK-safety & efficacy modelling
J Ribbing, GL Li, E Van Schaick, L Harnisch
ERS, Vienna, Austria, 2009
42009
Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies
J Ribbing, AC Hooker, EN Jonsson
Journal of Pharmacokinetics and Pharmacodynamics 35, 117-137, 2008
42008
The system can't perform the operation now. Try again later.
Articles 1–20